K. Nishio

Y. Ohe, K. Nishio, M. Kawaishi, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.

Kaoru Tanaka, K. Nishio, K. Doi, 2019, The Journal of clinical investigation.

N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression.

H. Izumi, K. Kohno, K. Nishio, 2009, Cancer research.

Cytoskeletons and antimitotic agents developed in Japan.

N. Saijo, K. Nishio, 1999, Anti-cancer drug design.

Mechanisms of Action of Cancer Chemotherapeutic Agents: Topoisomerase Inhibitors

N. Saijo, K. Nishio, Y. Koh, 2005 .

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.

N. Saijo, Y. Ohe, K. Nishio, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.

J. Soh, T. Mitsudomi, K. Nishio, 2020, Lung cancer.

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report

K. Nishio, T. Kikuchi, Satoshi Watanabe, 2021, Translational cancer research.

Multiplex gene‐panel testing for lung cancer patients

S. Toyooka, S. Ikeda, Y. Yatabe, 2020, Pathology international.

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

K. Nishio, S. Ikeda, A. Zimmermann, 2022, JTO clinical and research reports.

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

K. Goto, K. Nishio, Y. Nakanishi, 2019, The oncologist.

Establishment of a human leukemia subline resistant to the growth‐inhibitory effect of 12‐o‐tetradecanoylphorbol 13‐acetate (TPA) and showing non‐P‐glycoprotein‐mediated multi‐drug resistance

N. Saijo, Y. Fujiwara, K. Nishio, 1991, International journal of cancer.

Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells

K. Nishio, Y. Kodera, T. Tamura, 2009, Cancer science.

Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer.

K. Nishio, T. Hanafusa, S. Yoshida, 2013, Anticancer research.

Performance of Idylla™RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer

M. D. De Velasco, K. Nishio, T. Chikugo, 2022, International Journal of Clinical Oncology.

Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.

N. Saijo, H. Yokote, K. Nishio, 1996, Anticancer research.

Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms

K. Nishio, I. Matsumura, K. Sakai, 2017, International Journal of Hematology.

N-myc Downstream Regulated Gene 1 (NDRG1) Promotes Metastasis of Human Scirrhous Gastric Cancer Cells through Epithelial Mesenchymal Transition

H. Izumi, K. Nishio, M. Kuwano, 2012, PloS one.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3

H. Tsuda, K. Nishio, Y. Kodera, 2011, Breast Cancer Research.

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study.

J. Soh, T. Mitsudomi, K. Nishio, 2020, Translational lung cancer research.

Molecular Cancer Therapeutics Identification of cSrc as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to cSrc Inhibition

M. Fukuoka, K. Nishio, K. Yanagihara, 2010 .

Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions

S. Tomida, K. Nishio, S. Ishihara, 2014, Oncotarget.

Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer

S. Tomida, M. D. De Velasco, K. Nishio, 2015, SpringerPlus.

A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report

K. Nishio, K. Sakai, K. Ino, 2018, Oncology letters.

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

T. Yamanaka, I. Hyodo, K. Nishio, 2016, Cancer science.

Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.

K. Nishio, K. Okamoto, M. Takeda, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Single nucleotide polymorphism markers for low‐dose aspirin‐associated peptic ulcer and ulcer bleeding

K. Haruma, K. Nishio, Y. Fujimura, 2014, Journal of gastroenterology and hepatology.

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

S. Park, Tae-You Kim, K. Nishio, 2014, Gastric Cancer.

Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer

T. Yamanaka, M. Okada, T. Mitsudomi, 2015, Clinical Cancer Research.

The anti-HER 3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

K. Nishio, I. Okamoto, K. Okamoto, 2015 .

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.

K. Nishio, J. Tanizaki, K. Nakagawa, 2016, Lung cancer.

Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer

M. D. De Velasco, K. Nishio, T. Chikugo, 2022, International Journal of Clinical Oncology.

7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials

K. Eguchi, N. Saijo, Y. Ohe, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

K. Nishio, Kenichi Saito, T. Tamura, 2014, BMC Cancer.

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients

K. Nishio, M. Nishio, S. Okumura, 2005, British Journal of Cancer.

Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells

J. Usuda, N. Saijo, K. Nishio, 2002, Cancer Chemotherapy and Pharmacology.

Chemical constituents of a marine fungus, Arthrinium sacchari.

K. Nishio, T. Sugita, K. Kinoshita, 2011, Journal of natural products.

Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell‐cycle‐associated genes

Y. Sasaguri, H. Izumi, K. Kohno, 2010, Cancer science.

Differential roles of STAT 3 depending on the mechanism of STAT 3 activation in gastric cancer cells

K. Nishio, K. Yanagihara, I. Okamoto, 2014 .

Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells

K. Nishio, K. Yanagihara, I. Okamoto, 2011, British Journal of Cancer.

A Randomized Phase II Study Comparing Nivolumab With Carboplatin‐Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small‐Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Stud

T. Mitsudomi, C. Kitagawa, K. Nishio, 2017, Clinical lung cancer.

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer

K. Nishio, K. Nakagawa, S. Rothenberg, 2021, JCO precision oncology.

Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell.

K. Nishio, Kazuhisa Takahashi, F. Takahashi, 2007, Cancer letters.

Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy

Hiromasa Yamamoto, T. Ohira, M. Tsuboi, 2021, Cancer science.

Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG‐TR)

Hiromasa Yamamoto, T. Ohira, M. Tsuboi, 2020, Cancer science.

An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex largely circumvents in vitro cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles.

K. Nishio, M. Chikuma, Toshihiro Suzuki, 2012, Metallomics : integrated biometal science.

Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.

T. Mitsudomi, K. Nishio, H. Hayashi, 2015, Anticancer research.

Difference of EGFR-Binding Proteins between Wild Type and Mutant EGFR

K. Nishio, T. Kuroki, T. Ohmori, 2009 .

Translational studies for target-based drugs

N. Saijo, Y. Fujiwara, K. Nishio, 2005, Cancer Chemotherapy and Pharmacology.

Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III

T. Itakura, K. Nishio, J. Fukai, 2008, Cancer science.

A phase II study of gefitinib monotherapy for chemotherapy-naive patients with non-small cell lung cancer

K. Nishio, M. Fujimura, Y. Ishiura, 2005 .

Clinical Response to Everolimus of EGFR–Mutation‐Positive NSCLC With Primary Resistance to EGFR TKIs

K. Nishio, H. Matsuoka, A. Koyama, 2017, Clinical lung cancer.

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

M. Fukuoka, K. Nishio, I. Okamoto, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR mutation in various tissues

H. Yokote, K. Nishio, T. Arao, 2006, Cancer Chemotherapy and Pharmacology.

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib

K. Nishio, T. Tamura, T. Tamura, 2006, British Journal of Cancer.

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).

K. Nishio, S. Ikeda, K. Azuma, 2022, Lung cancer.

Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib

Y. Maehara, T. Mitsudomi, S. Tomida, 2015, PloS one.

Title Ciliated muconodular papillary tumors of the lung withKRAS / BRAF / AKT 1 mutation

L. Prentice, T. Nagayasu, N. Yamasaki, 2019 .

Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation

L. Prentice, T. Nagayasu, N. Yamasaki, 2017, Diagnostic Pathology.

An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.

T. Mitsudomi, S. Tomida, M. D. De Velasco, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma

K. Nishio, I. Okamoto, J. Tanizaki, 2012, Acta oncologica.

METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society

S. Toyooka, S. Ikeda, Y. Yatabe, 2021, Haigan.

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

M. Fukuoka, K. Nishio, I. Okamoto, 2013, Cancer Chemotherapy and Pharmacology.

Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.

T. Ohira, N. Ikeda, T. Nagao, 2014, Lung Cancer.

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.

Kaoru Tanaka, K. Nishio, I. Okamoto, 2012, Clinical lung cancer.

Drug resistance in lung cancer.

N. Saijo, K. Nishio, H. Fukumoto, 1999, Current opinion in oncology.

A Computational Model for Quantitative Analysis of Cell Cycle Arrest and Its Contribution to Overall Growth Inhibition by Anticancer Agents

J. Usuda, N. Saijo, K. Nishio, 2000, Japanese journal of cancer research : Gann.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)

H. Aburatani, H. Ueno, S. Toyooka, 2020, International Journal of Clinical Oncology.

Prognostic implications of the nuclear localization of Y‐box‐binding protein‐1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/MVP and P‐glycoprotein expression

N. Wake, Y. Oda, K. Nishio, 2007, Cancer science.

FGFR2 gene amplification and clinicopathological features in gastric cancer

K. Matsumoto, I. Oda, K. Nishio, 2012, British Journal of Cancer.

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver

N. Saijo, K. Nishio, T. Tamura, 2001, Japanese journal of cancer research : Gann.

Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.

K. Nishio, K. Furuta, K. Sakai, 2011, Anticancer research.

BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer

Pham Nguyen Quy, K. Nishio, M. Muto, 2020, Pancreas.

Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin

N. Saijo, K. Nishio, H. Fukumoto, 2002, Japanese journal of cancer research : Gann.

Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin

M. D. De Velasco, K. Nishio, S. Koinuma, 2014, PloS one.

P3-103: Evaluation of Epidermal Growth Factor Receptor Mutation Status in Serum DNA as a Predictor of Response to Gefitinib (IRESSA)

K. Nishio, M. Fujimura, H. Kimura, 2007 .

Evaluation of synergism by a novel three‐dimensional model for the combined action of cisplatin and etoposide on the growth of a human small‐cell lung‐cancer cell line, SBC‐3

N. Saijo, K. Nishio, K. Fukuoka, 1997, International journal of cancer.

Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study

Y. Kogure, M. Satouchi, K. Nishio, 2014, Oncotarget.

SY1. building the foundation for investigator-initiated clinical trial

P. Jänne, H. Katayama, M. Kudo, 2012 .

A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis

N. Saijo, K. Nishio, H. Arioka, 1996, Japanese journal of cancer research : Gann.

Novel Single Nucleotide Polymorphism Markers for Low Dose Aspirin-Associated Small Bowel Bleeding

K. Haruma, K. Nishio, Y. Fujimura, 2013, PloS one.

Deletional mutant EGFR detected in circulating tumor-derived DNA from lung cancer patients treated with gefitinib.

K. Nishio, H. Fukumoto, T. Tamura, 2005 .

Establishment of a human small‐cell lung‐cancer subline resistant to okadaic acid

S. Kudoh, N. Saijo, S. Kudoh, 1994, International journal of cancer.

mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.

N. Saijo, Kaoru Tanaka, K. Nishio, 2009, Cancer research.

Characterization of a Taxol‐resistant Human Small‐cell Lung Cancer Cell Line

T. Ohira, N. Saijo, K. Nishio, 1994, Japanese journal of cancer research : Gann.

Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines.

N. Saijo, K. Nishio, T. Tamura, 2002, Lung cancer.

Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer

Y. Fujiwara, K. Nishio, O. Katoh, 2000, International journal of cancer.

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene

N. Saijo, H. Yokote, K. Nishio, 1997, Japanese journal of cancer research : Gann.

Osteopontin modulates malignant pleural mesothelioma cell functions in vitro.

T. Nakano, K. Nishio, K. Fukuoka, 2009, Anticancer research.

Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin

M. Fukuoka, K. Nishio, E. Hatashita, 2001, International journal of cancer.

Genistein, a Tyrosine Kinase Inhibitor, Decreased the Affinity of p56lck to β-Chain of Interleukin-2 Receptor in Human Natural Killer (NK)-Rich Cells and Decreased NK-Mediated Cytotoxicity

N. Saijo, K. Nishio, Y. Heike, 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance

K. Nishio, K. Nakagawa, K. Yonesaka, 2017, International journal of cancer.

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.

T. Yamanaka, K. Tamura, Masato Takahashi, 2018, Breast.

Differential gene expression profiles and identification of the genes relevant to clinicopathologic factors in colorectal cancer selected by cDNA array method in combination with principal component analysis.

N. Saijo, K. Nishio, H. Yamaue, 2003, International journal of oncology.

In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice

T. Ohira, N. Saijo, K. Nishio, 2004, Cancer Chemotherapy and Pharmacology.

Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.

N. Saijo, K. Nishio, H. Kurokawa, 1997, British Journal of Cancer.

Ouabain‐resistant non‐small‐cell lung‐cancer CELL LINE SHOWS COLLATERAL SENSITIVITY TO cis‐diamminedichloroplatinum(II) (CDDP)

N. Saijo, K. Nishio, M. Adachi, 1994, International journal of cancer.

Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors

K. Nishio, T. Okawara, R. Islam, 2012, Investigational New Drugs.

Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus Bendamustine

K. Nishio, I. Matsumura, K. Sakai, 2021 .

Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells.

N. Saijo, K. Nishio, H. Kurokawa, 1999, Oncology reports.

Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin.

N. Saijo, Y. Fujiwara, K. Nishio, 1992, Cancer research.

Guidance for peptide vaccines for the treatment of cancer

K. Okuno, J. Furuse, Y. Ohashi, 2014, Cancer science.

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

K. Matsumoto, K. Nishio, I. Okamoto, 2013, Oncogene.

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2020, British Journal of Cancer.

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, Y. Tanigawara, 2012, Oncology reports.

FGF3/FGF4 Ampliﬁcation and Multiple Lung Metastases in Responders to Sorafenib in Hepatocellular Carcinoma

T. Utsunomiya, M. Kudo, S. Hagiwara, 2013 .

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

K. Nishio, T. Tamura, Yasuhide Yamada, 2011, Clinical Cancer Research.

In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells

N. Saijo, K. Nishio, H. Arioka, 1997, Japanese journal of cancer research : Gann.

hnRNP L enhances sensitivity of the cells to KW‐2189

K. Yano, H. Kato, N. Saijo, 2004, International journal of cancer.

Proximal 5'-flanking sequence of the human gamma-glutamylcysteine synthetase heavy subunit gene is involved in cisplatin-induced transcriptional up-regulation in a lung cancer cell line SBC-3.

J. Usuda, N. Saijo, K. Nishio, 1997, Biochemical and biophysical research communications.

Identification ofcis-Acting DNA Elements of the Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene

N. Saijo, K. Nishio, H. Arioka, 1997 .

In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

N. Saijo, K. Nishio, H. Fukumoto, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

M. D. De Velasco, K. Nishio, B. Davies, 2019, JCI insight.

Identification of a FGFR3-TACC3 fusion in esophageal cancer.

K. Nishio, T. Nakajima, T. Fujino, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival

S. Tomida, M. D. De Velasco, K. Nishio, 2014, Oncotarget.

Role of multidrug resistance-associated protein 1 in the pathogenesis of allergic airway inflammation.

Yoichi M. Ito, K. Nishio, Mayumi Ota, 2009, American journal of physiology. Lung cellular and molecular physiology.

Drug Accumulation and Efflux Do not Contribute to Acquired Gefitinib Resistance

N. Saijo, K. Nishio, T. Kuroki, 2009 .

AZD 2171 Shows Potent AntitumorActivityAgainst Gastric Cancer OverExpressing Fibroblast Growth Factor Receptor 2 / Keratinocyte Growth Factor Receptor

N. Saijo, K. Nishio, K. Fukuoka, 2007 .

Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562/TPA cells.

J. Usuda, H. Kato, N. Saijo, 2003, International journal of oncology.

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC

S. Tomida, K. Nishio, Y. Fukuda, 2022, JTO clinical and research reports.

Genital mucosal melanoma with somatic SF3B1 R625C mutation

A. Kawada, K. Nishio, N. Oiso, 2018, European Journal of Dermatology.

Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells

K. Nishio, T. Takeda, M. Imano, 2017, Oncotarget.

Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.

N. Saijo, Y. Fujiwara, K. Nishio, 1990, British Journal of Cancer.

Characterization of an etoposide-resistant human ovarian cancer cell line

T. Ohira, N. Saijo, K. Nishio, 2004, Cancer Chemotherapy and Pharmacology.

Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.

N. Saijo, K. Nishio, F. Kanzawa, 1995, Cancer research.

Incidence of carnitine deficiency in patients with cancer pain: A pilot study

K. Nishio, H. Matsuoka, Masatomo Otsuka, 2017, Molecular and clinical oncology.

[Effect of cisplatin on cell cycle regulators].

N. Saijo, K. Nishio, 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

Establishment and molecular profiling of a novel human pancreatic cancer panel for 5‐FU

T. Oda, Y. Aoyagi, A. Ochiai, 2008, Cancer science.

[Molecular targeted therapies].

K. Nishio, H. Kimura, 2010, Nihon rinsho. Japanese journal of clinical medicine.

Reversal of multidrug resistance by tyrosine‐kinase inhibitors in a non‐P‐glycoprotein‐mediated multidrug‐resistant cell line

K. Nishio, H. Niitani, Y. Takeda, 1994, International journal of cancer.

Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB 2 mutation : unusual genetics , unusual clinical course

K. Nishio, T. Nakajima, T. Fujino, 2017 .

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Y. Ohe, K. Kiura, K. Goto, 2021, JTO clinical and research reports.

P3.01-75 RELAY+, an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC

K. Nishio, K. Suzukawa, M. Nishio, 2018, Journal of Thoracic Oncology.

A Pilot Proficiency Testing Study for Assessing Cancer Gene Panel using Patient Samples and Next-generation Sequencing in Japan

Y. Yatabe, Misa Fuchioka, K. Nishio, 2021 .

Apoptosis induced by etoposide in small-cell lung cancer cell lines

N. Saijo, K. Nishio, Y. Heike, 2004, Cancer Chemotherapy and Pharmacology.

Preferential Binding of E7010 to Murine β3‐Tubulin and Decreased β3‐Tubulin in E7010‐resistant Cell Lines

N. Saijo, K. Nishio, H. Fukumoto, 1998, Japanese journal of cancer research : Gann.

Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

M. Kudo, Y. Minami, K. Ueshima, 2021 .

In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines

N. Saijo, Y. Ohe, Y. Fujiwara, 2004, Cancer Chemotherapy and Pharmacology.

SRPX2 Is a Novel Chondroitin Sulfate Proteoglycan That Is Overexpressed in Gastrointestinal Cancer

Kaoru Tanaka, K. Nishio, K. Yanagihara, 2012, PloS one.

SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion

Kaoru Tanaka, H. Yokote, K. Nishio, 2009, International journal of cancer.

Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II).

N. Saijo, Y. Fujiwara, K. Nishio, 1992, The Journal of clinical investigation.

Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes

K. Eguchi, N. Saijo, Y. Ohe, 1996, Cancer Chemotherapy and Pharmacology.

Genetic Pro ﬁ ling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA

K. Goto, K. Nishio, Y. Nakanishi, 2019 .

Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib

K. Nishio, K. Yanagihara, I. Okamoto, 2013 .

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

K. Nishio, K. Yanagihara, I. Okamoto, 2012, Molecular Cancer Therapeutics.

Preclinical Development Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib ( PF-02341066 ) in Gastric Cancer Positive for MET Ampli fi cation

K. Nishio, K. Yanagihara, I. Okamoto, 2012 .

Serpina3n, Dominantly Expressed in Female Osteoblasts, Suppresses the Phenotypes of Differentiated Osteoblasts in Mice.

K. Nishio, K. Okada, K. Sakai, 2018, Endocrinology.

Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer

K. Nishio, N. Nonomura, M. Matsushita, 2022, Scientific Reports.

Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles.

N. Nishiyama, K. Kataoka, K. Nishio, 2003, Bioconjugate chemistry.

Human Breast Cancers upon Nuclear Localization of Y-Box Binding Protein-1 in Depends α Expression of HER 2 and Estrogen Receptor

K. Shirouzu, Kazutaka Nakashima, H. Yamana, 2008 .

Molecular determinants of UCN‐01‐induced growth inhibition in human lung cancer cells

J. Usuda, H. Kato, N. Saijo, 2000, International journal of cancer.

Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2022, Lung cancer.

Activation-Induced Apoptosis of Peripheral Lymphocytes Treated with 7-Hydroxystaurosporine, UCN-01

J. Usuda, N. Saijo, Y. Ohe, 1999, Investigational New Drugs.

Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period

M. D. De Velasco, K. Nishio, M. Sekimoto, 2021, Hepatology International.

Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

N. Saijo, Y. Ohe, Y. Fujiwara, 1992, British Journal of Cancer.

In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line.

N. Saijo, K. Nishio, F. Kanzawa, 2003, Lung cancer.

Antitum or Activity of O xaliplatin, 5-FU and Paclitaxel G iven Alone or in Com bination with ZD 1839 in H um an Gastric Carcinom a Cells in vitro

N. Saijo, K. Nishio, Jin-Hyoung Kang, 2003 .

Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells

N. Saijo, S. Kudoh, K. Nishio, 1999, Cancer Chemotherapy and Pharmacology.

Ectopic p16ink4 expression enhances CPT‐11‐induced apoptosis through increased delay in S‐phase progression in human non‐small‐cell‐lung‐cancer cells

J. Usuda, N. Saijo, K. Nishio, 2000 .

Forkhead Box Q1 Expression Is Associated With Tumor Location of Right-Sided Colon, But Not With Acquisition of Oxaliplatin Resistance in Colorectal Cancer

T. Yamano, N. Tomita, K. Nishio, 2021 .

Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells

Hiroki Sato, K. Nishio, T. Takata, 2016, Archives of Pharmacal Research.

Precision cancer genome testing needs proficiency testing involving all stakeholders

Y. Yatabe, Misa Fuchioka, K. Nishio, 2022, Scientific reports.

Antitumor action of the PKC activator gnidimacrin through cdk2 inhibition

N. Saijo, K. Nishio, H. Wakasugi, 2001, International journal of cancer.

Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.

Masato Terashima, Masatoshi Kudo, Masayuki Kitano, 2015, Cancer letters.

Potential anti-angiogenesis effects of p-terphenyl compounds from Polyozellus multiplex.

K. Nishio, Ikuko Nagasawa, Akira Kaneko, 2014, Journal of natural products.

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

K. Goto, K. Nishio, Y. Nakanishi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance.

N. Saijo, K. Nishio, H. Arioka, 1995, Biochemical and biophysical research communications.

A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20 : a case report and literature review.

N. Matsumura, K. Nishio, S. Minamiguchi, 2021, The oncologist.

Contents Vol. 34, 2016

Y. Imai, M. Kudo, Y. Minami, 2016, Digestive Diseases.

Antiangiogenic metabolites from a marine-derived fungus, Hypocrea vinosa.

K. Nishio, T. Sugita, K. Kinoshita, 2010, Journal of natural products.

Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f

N. Saijo, K. Nishio, T. Ishida, 1998, Japanese journal of cancer research : Gann.

Genetic profile of adult T‐cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV‐1 strains

K. Karube, K. Nishio, H. Masuzaki, 2021, Cancer science.

A phase I and pharmacokinetic/pharmacodynamic study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with solid tumor

K. Nishio, T. Otsuki, T. Tamura, 2007 .

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

K. Nishio, Daisuke Ishikawa, T. Sekiya, 2022, Cancers.

Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer

Young Hak Kim, T. Honjo, K. Nishio, 2022, Science Translational Medicine.

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

P. Jänne, P. Janne, K. Azuma, 2012, British Journal of Cancer.

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

P. Jänne, K. Nishio, I. Okamoto, 2011, Clinical Cancer Research.

A Novel Antitumor Antibiotic, KW‐2189 Is Activated by Carboxyl Esterase and Induces DNA Strand Breaks in Human Small Cell Lung Cancer Cells

T. Ohira, N. Saijo, K. Nishio, 1994, Japanese journal of cancer research : Gann.

Influence of novel supramolecular substance, [2] rotaxane, on the caspase signaling pathway in melanoma and colon cancer cells in vitro.

K. Nishio, T. Takata, Y. Fujita, 2013, Journal of pharmacological sciences.

The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP)

N. Saijo, Y. Fujiwara, K. Nishio, 1993, Japanese journal of cancer research : Gann.

Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.

N. Saijo, Y. Fujiwara, K. Nishio, 1992, Journal of the National Cancer Institute.

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

Masato Terashima, Shuta Tomida, Kazuko Sakai, 2015, PloS one.

KDR Kinase Inhibitor Isolated from the Mushroom Boletopsis leucomelas.

K. Nishio, Akira Kaneko, K. Kinoshita, 2010, Journal of natural products.

Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.

Y. Sugiyama, N. Nishiyama, K. Kataoka, 2003, Cancer research.

N‐Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor

C. Shimizu, Y. Fujiwara, Kaoru Tanaka, 2008, Cancer science.

Lines Amphotericin B in Cisplatin-resistant Human Lung Cancer Cell Modulation of Cisplatin Sensitivity and Accumulation by Updated Version

Yasuhiro, Toshihiko, K. Nishio, 2006 .

Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.

N. Saijo, Y. Fujiwara, K. Nishio, 1991, Cancer research.

Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line

N. Saijo, Y. Fujiwara, K. Nishio, 1991, Japanese journal of cancer research : Gann.

In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model

N. Saijo, K. Nishio, K. Fukuoka, 1999, Cancer Chemotherapy and Pharmacology.

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

K. Nishio, M. Kawaishi, T. Tamura, 2006, Clinical Cancer Research.

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells

K. Nishio, M. Kuwano, M. Ono, 2017, Oncotarget.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification

P. Jänne, M. Fukuoka, K. Nishio, 2010, Cancer science.

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Kaoru Tanaka, K. Nishio, A. Tsuya, 2021, Clinical Cancer Research.

Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.

Mayumi Ono, Satoshi Hattori, Akihiko Kawahara, 2008, Cancer research.

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

K. Nishio, T. Tamura, M. Sekijima, 2005, Lung cancer.

Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.

N. Matsumura, K. Nishio, M. Mandai, 2019, Gynecologic oncology.

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

K. Nishio, K. Nakagawa, Y. Komoike, 2018, Breast Cancer.

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer

K. Nishio, T. Sudo, M. Tanioka, 2014, Breast Cancer Research and Treatment.

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification

K. Nishio, I. Okamoto, J. Tanizaki, 2011, Oncogene.

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer

M. D. De Velasco, K. Nishio, B. Davies, 2016, Oncotarget.

p16INK4 Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors

J. Yokota, N. Saijo, H. Yokote, 1997, Japanese journal of cancer research : Gann.

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

K. Nishio, Y. Nakanishi, K. Azuma, 2019, Cancer.

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2

Kaoru Tanaka, K. Nishio, J. Tanizaki, 2018, Oncotarget.

Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact

K. Nishio, K. Sakai, K. Ino, 2020, Cancers.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

T. Mitsudomi, S. Tomida, Kaoru Tanaka, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

K. Nishio, K. Nakagawa, Y. Chiba, 2018, Oncogene.

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

Koichi Goto, Masahiro Fukuoka, Nobuyuki Yamamoto, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer

M. D. De Velasco, Motoyoshi Tanaka, K. Nishio, 2014, Carcinogenesis.

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer

M. D. De Velasco, K. Nishio, K. Fujita, 2021, Cancers.

Hypoxia induces gefitinib resistance in non‐small‐cell lung cancer with both mutant and wild‐type epidermal growth factor receptors

K. Nishio, Kazuhisa Takahashi, F. Takahashi, 2012, Cancer Science.

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

M. Kudo, N. Saijo, K. Nishio, 2011, Molecular Cancer Therapeutics.

FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.

Kaoru Tanaka, M. D. De Velasco, K. Nishio, 2010, Cancer research.

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis

H. Ogata, M. Kudo, H. Kashida, 2020, Scientific Reports.

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Kenichi Suda, Masaki Shimoji, Toyoaki Hida, 2015, Clinical Cancer Research.

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter

K. Nishio, I. Okamoto, K. Nakagawa, 2014, Oncology letters.

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer

Y. Yatabe, T. Mitsudomi, S. Tomida, 2015, Scientific Reports.

Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes.

M. Shibuya, J. Yokota, N. Saijo, 1991, British Journal of Cancer.

Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.

J. Soh, T. Mitsudomi, K. Nishio, 2021, Clinical lung cancer.

Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens

T. Ohira, N. Ikeda, T. Mitsudomi, 2019, Cancer science.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study

Roy R. L. Bastien, H. Feilotter, B. Tops, 2018, BMC Cancer.

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2017, BMC Cancer.

MEK inhibitors against MET-amplified non-small cell lung cancer

Yusuke Nakamura, T. Mitsudomi, S. Tomida, 2016, International journal of oncology.

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

Yusuke Nakamura, T. Mitsudomi, S. Tomida, 2016, Clinical Cancer Research.

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.

T. Mitsudomi, S. Tomida, K. Nishio, 2015, Lung cancer.

Novel Water-Soluble Derivatives of Docosahexaenoic Acid Increase Diacylglycerol Production Mediated by Phosphatidylcholine-Specific Phospholipase C

N. Saijo, K. Nishio, K. Yazawa, 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

RPN2 gene confers docetaxel resistance in breast cancer

Yusuke Yamamoto, Takahiro Ochiya, Kimi Honma, 2008, Nature Medicine.

Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.

A. Roter, M. D. De Velasco, K. Nishio, 2017, Cancer letters.

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.

S. Tomida, K. Nishio, Y. Iwamoto, 2020, JAMA oncology.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

H. Mukai, Y. Ohashi, K. Nishio, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 5169: Novel target molecules for treatment of cancer of unknown primary

K. Nishio, K. Nakagawa, T. Kurata, 2018, Tumor Biology.

Abstract 3993: A microarray-based gene expression analysis identified diagnostic biomarkers for unknown primary cancer

K. Nishio, Y. Koh, K. Nakagawa, 2014 .

Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer

S. Hirohashi, T. Ochiya, K. Nishio, 2005, Cancer science.

A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination.

T. Ochiya, F. Takeshita, K. Nishio, 2006, Cancer research.

ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model

Y. Shiratori, K. Nishio, K. Yanagihara, 2006, International journal of cancer.

RASGRP2 Suppresses Apoptosis via Inhibition of ROS Production in Vascular Endothelial Cells

K. Nagamine, K. Nishio, T. Hori, 2019, TheScientificWorldJournal.

Conditional PTEN-deficient mice as a prostate cancer chemoprevention model.

M. D. De Velasco, K. Nishio, Y. Hatanaka, 2015, Asian Pacific journal of cancer prevention : APJCP.

Increased cytotoxic effects of photodynamic therapy in IL‐6 gene transfected cells via enhanced apoptosis

J. Usuda, H. Kato, T. Okunaka, 2001, International journal of cancer.

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Lung cancer.

O3-15-2CHRONIC NICOTINE EXPOSURE MEDIATES RESISTANCE TO EGFR-TKI IN EGFR-MUTATED LUNG CANCER VIA EGFR SIGNAL

S. Tomida, K. Nishio, K. Okamoto, 2014 .

1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line.

N. Saijo, K. Nishio, Y. Iwamoto, 1996, Anticancer research.

Clinicopathological and genetic differences between low‐grade and high‐grade colorectal mucinous adenocarcinomas

K. Okuno, S. Tomida, M. D. De Velasco, 2015, Cancer.

A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer

Yuichi Takiguchi, Hirofumi Mukai, Nobuyuki Yamamoto, 2013, PloS one.

A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer

K. Nishio, I. Okamoto, K. Takezawa, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production

M. D. De Velasco, K. Nishio, H. Shiozaki, 2013, Oncotarget.

Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation

Y. Yatabe, T. Mitsudomi, N. Saijo, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

T. Tahira, K. Hayashi, R. Rosell, 2012, PloS one.

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

P. Jänne, M. Fukuoka, K. Nishio, 2009, Clinical Cancer Research.

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models

Fumiaki Koizumi, N. Saijo, K. Nishio, 2004, Cancer science.

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Wataru Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa, 2010, Molecular Cancer Therapeutics.

Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth.

K. Nishio, Kazuhisa Takahashi, F. Takahashi, 2003, Cancer letters.

Differential osteopontin expression in lung cancer.

K. Nishio, J. Zhang, F. Takahashi, 2001, Cancer letters.

Clinical and immune profiling for cancer of unknown primary site

S. Tomida, K. Nishio, J. Tanizaki, 2019, Journal of Immunotherapy for Cancer.

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2016, Cancer science.

Growth Stimulation of Non–Small Cell Lung Cancer Cell Lines by Antibody against Epidermal Growth Factor Receptor Promoting Formation of ErbB2/ErbB3 Heterodimers

N. Shimizu, K. Nishio, K. Takeuchi, 2007, Molecular Cancer Research.

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

Kaoru Tanaka, K. Nishio, K. Doi, 2019, Oncogenesis.

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Y. Ichinose, K. Kiura, K. Goto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells

T. Takasaki, K. Nishio, R. Sugiura, 2022, Cells.

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

K. Nishio, I. Okamoto, K. Okamoto, 2014, Oncotarget.

HOXA10 expression profiling in prostate cancer

M. D. De Velasco, K. Nishio, Y. Hatanaka, 2019, The Prostate.

SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma.

K. Nishio, O. Yoshie, T. Arao, 2013, Blood.

in adult T-cell leukemia/lymphoma HDAC8 and induces expression of FRA-2 is a direct target gene of SOX4

K. Nishio, O. Yoshie, T. Arao, 2013 .

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

T. Yamanaka, E. Baba, N. Sugimoto, 2018, The oncologist.

Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP

N. Saijo, Y. Fujiwara, K. Nishio, 1992, Japanese journal of cancer research : Gann.

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.

M. Ando, K. Yonemori, C. Shimizu, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Element array by scanning X-ray fluorescence microscopy after cis-diamminedichloro-platinum(II) treatment.

T. Ishikawa, Y. Nishino, K. Tamasaku, 2005, Cancer research.

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer

Toshio Shimizu, K. Nishio, I. Okamoto, 2020, Cancer Chemotherapy and Pharmacology.

Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.

Kaoru Tanaka, K. Nishio, I. Okamoto, 2010, Cancer research.

Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe

H. Aburatani, S. Hirota, Y. Kaneda, 2016 .

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

K. Okuno, S. Tomida, M. D. De Velasco, 2015, International journal of oncology.

Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy

M. Wallace, H. Wolfsen, H. Matsumoto, 2020, Esophagus.

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study

J. Soh, T. Mitsudomi, K. Nishio, 2020, Translational lung cancer research.

Enhancement of Epidermal Growth Factor Receptor-degradation Pathway in Acquired Gefitinib-resistant Human Non-small Cell Lung Cancer Cell Lines

M. Matsuda, N. Saijo, K. Nishio, 2004 .

The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine

A. Ochiai, Y. Kanai, E. Morii, 2021, Pathology international.

Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.

Y. Nishimura, K. Nishio, I. Okamoto, 2012, Anticancer research.

Abrogation of the interaction between osteopontin and αvβ3 integrin reduces tumor growth of human lung cancer cells in mice

Y. Ohe, K. Nishio, Kazuhisa Takahashi, 2007 .

Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.

Y. Ohe, K. Nishio, Kazuhisa Takahashi, 2007, Lung cancer.

Tumor volume determines the feasibility of cell‐free DNA sequencing for mutation detection in non‐small cell lung cancer

T. Ohira, Koichi Yoshida, M. Kakihana, 2016, Cancer science.

Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.

M. Fukuoka, K. Nishio, I. Okamoto, 2007, Lung cancer.

Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.

N. Saijo, Y. Fujiwara, K. Nishio, 1992, Biochemical and biophysical research communications.

Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma

T. Ohira, T. Yamanaka, N. Ikeda, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Personalized medicine and proteomics: lessons from non-small cell lung cancer.

György Marko-Varga, Atsushi Ogiwara, Toshihide Nishimura, 2007, Journal of proteome research.

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib

N. Izumi, K. Nishio, Y. Osaki, 2015, Oncotarget.

Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa® (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line in vitro and in vivo

N. Saijo, M. Mori, K. Nishio, 2002, International journal of cancer.

Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients

C. Shimizu, Y. Fujiwara, Yoon-Koo Kang, 2006, Breast Cancer Research and Treatment.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kaoru Tanaka, K. Nishio, Y. Hasegawa, 2018, Clinical Cancer Research.

Effects of β- and γ-carboline derivatives on DNA topoisomerase activities

T. Ohira, N. Saijo, K. Nishio, 1996 .

TGF-β induces sustained upregulation of SNAI1 and SNAI2 through Smad and non-Smad pathways in a human corneal epithelial cell line.

Koji Sugioka, Yoshikazu Shimomura, Daisuke Tamura, 2011, Investigative ophthalmology & visual science.

Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells

Kenji Yasuda, Yohei Miyagi, Mathias Girault, 2014, PloS one.

Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer

K. Nishio, K. Sakai, K. Ino, 2020, Oncology letters.

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing

K. Nishio, K. Sakai, K. Ino, 2019, Scientific Reports.

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2016, Cancer science.

Guidance for ALK Gene Testing in Lung Cancer Patients

K. Nishio, K. Nakagawa, K. Hagiwara, 2012 .

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

K. Okuno, S. Tomida, M. D. De Velasco, 2014, International journal of oncology.

Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements

K. Okuno, S. Tomida, K. Nishio, 2014 .

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer

M. Tsuboi, K. Eguchi, N. Saijo, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

P. Jänne, K. Nishio, I. Okamoto, 2016, Oncogene.

Phase II study of erlotinib plus tivantinib ( ARQ 197 ) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI , ge fi tinib or erlotinib

T. Mitsudomi, S. Akinaga, K. Kubota, 2016 .

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

K. Nishio, M. Nishio, K. Sakai, 2013, Cancer science.

An early event of EGFR mutation in pleomorphic carcinoma of the lung

K. Nishio, K. Hiroshima, K. Tatsumi, 2011, International Journal of Clinical Oncology.

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6

N. Saijo, Y. Ohe, K. Nishio, 2001, Japanese journal of cancer research : Gann.

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

Young Hak Kim, T. Mitsudomi, K. Nishio, 2016, Molecular Cancer Therapeutics.

Inhibition of &bgr;-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies

S. Tomida, M. D. De Velasco, K. Nishio, 2017, Molecular carcinogenesis.

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

T. Ohira, T. Yamanaka, N. Ikeda, 2010, Clinical Cancer Research.

Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer

M. Fukuoka, K. Nishio, I. Okamoto, 2008, Cancer science.

Identification of expressed genes characterizing long-term survival in malignant glioma patients

K. Nishio, R. Tanaka, M. Sekijima, 2006, Oncogene.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines

M. D. De Velasco, K. Nishio, K. Sakai, 2014, SpringerPlus.

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, International journal of oncology.

A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer

N. Saijo, C. Shimizu, K. Nishio, 2009, International Journal of Clinical Oncology.

A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer

J. Minna, N. Saijo, K. Nishio, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cell Lung Cancer Small − Positive Non − Resistance to ALK Inhibitors in EML 4-ALK Activation of HER Family Signaling as a Mechanism of Acquired

Kaoru Tanaka, K. Nishio, I. Okamoto, 2013 .

Clinical outcome for EML 4-ALK-positive patients with advanced non-small-cell lung cancer treated with fi rst-line platinum-based chemotherapy

K. Nishio, I. Okamoto, M. Takeda, 2012 .

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer

K. Nishio, Y. Komoike, T. Kurata, 2015, British Journal of Cancer.

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)

K. Nishio, K. Miyamoto, M. Fujimura, 2007, British Journal of Cancer.

High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients

K. Nishio, T. Tamura, H. Kunitoh, 2006, Cancer science.

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing

K. Goto, K. Nishio, Y. Nakanishi, 2018, Cancer science.

Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.

T. Mitsudomi, K. Nishio, K. Sakai, 2016, Lung cancer.

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Kaoru Tanaka, K. Nishio, I. Okamoto, 2015, Oncotarget.

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

Yusuke Nakamura, S. Tomida, M. D. De Velasco, 2016, Molecular Cancer Therapeutics.

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Kaoru Tanaka, K. Nishio, K. Azuma, 2019, Scientific Reports.

Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

M. Fukuoka, K. Nishio, I. Okamoto, 2010, Molecular Cancer Therapeutics.

KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

K. Nishio, J. Tanizaki, K. Nakagawa, 2021, Clinical Cancer Research.

Fc g R 2 A and 3 A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER 2-positive breast cancer

M. Ando, K. Yonemori, C. Shimizu, 2011 .

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile

Masanori Kato, Kimihiro Ito, K. Nishio, 2013, Molecular Cancer Therapeutics.

EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer

K. Nishio, Kazuyoshi Watanabe, M. Fujimura, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line

T. Itakura, H. Yokote, K. Nishio, 2008, Molecular Cancer Therapeutics.

Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.

K. Okuno, K. Nishio, K. Sakai, 2015, Biochemical and biophysical research communications.

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody

M. Kudo, Y. Minami, S. Hagiwara, 2021, Liver Cancer.

Guidelines for clinical evaluation of anti‐cancer drugs

Toshio Shimizu, K. Nishio, A. Ohtsu, 2021, Cancer science.

Developments for a growing Japanese patient population: facilitating new technologies for future health care.

Fumio Nomura, Tadashi Kondo, Toshihide Nishimura, 2011, Journal of proteomics.

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples

K. Nishio, K. Azuma, I. Okamoto, 2015, Oncotarget.

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

K. Nishio, K. Azuma, Y. Fukuda, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib

K. Sugio, K. Nishio, K. Nabeshima, 2021, JTO clinical and research reports.

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients

K. Nishio, M. Nishio, K. Sakai, 2019, Cancer science.

Detection of the T 790 M mutation of EGFR in plasma of advanced non – small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors ( West Japan oncology group 8014 LTR study )

T. Ohira, S. Bandoh, K. Nishio, 2016 .

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma

K. Okuno, K. Nishio, H. Shiozaki, 2013, International journal of oncology.

act of Serum Hepatocyte Growth Factor on Treatment ponse to Epidermal Growth Factor Receptor Tyrosine ase Inhibitors in Patients with Non–Small Cell

T. Ohira, N. Ikeda, N. Saijo, 2010 .

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

K. Nishio, M. Fujimura, Y. Nakatsumi, 2007, Cancer.

Targeting MET Amplification as a New Oncogenic Driver

K. Nishio, I. Okamoto, J. Tanizaki, 2014, Cancers.

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

K. Nishio, K. Nakagawa, H. Hayashi, 2014, Drug design, development and therapy.

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

K. Nishio, I. Okamoto, M. Takeda, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)

T. Ohira, K. Nishio, K. Azuma, 2020, Molecular oncology.

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study

T. Ohira, K. Nishio, K. Azuma, 2020, Cancer.

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2019, Lung cancer.

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2019, Lung cancer.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, K. Azuma, S. Hattori, 2016, Scientific Reports.

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

K. Nishio, I. Okamoto, K. Nakagawa, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.

T. Mitsudomi, R. McCormack, M. Satouchi, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Serum HGF on Treatment Response to EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Adenocarcinoma

T. Ohira, N. Ikeda, N. Saijo, 2010 .

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer

Toshio Shimizu, K. Nishio, T. Satoh, 2015, PloS one.

Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer.

Toshio Shimizu, K. Nishio, T. Satoh, 2015, Anticancer research.

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Yusuke Nakamura, M. Kudo, M. D. De Velasco, 2017, International journal of oncology.

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study

H. Ueno, Y. Ohashi, K. Nishio, 2015, Cancer science.

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer

M. Kudo, S. Tomida, M. D. De Velasco, 2014, Molecular Cancer.

Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease

Toshio Shimizu, K. Nishio, N. Isogai, 2016, Investigational New Drugs.

Bioinformatics Analysis of Gut Microbiota and CNS Transcriptome in Virus-Induced Acute Myelitis and Chronic Inflammatory Demyelination; Potential Association of Distinct Bacteria With CNS IgA Upregulation

K. Nishio, Ikuo Tsunoda, M. Fujita, 2020, Frontiers in Immunology.

Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis

M. Kudo, K. Ueshima, T. Sakurai, 2021, Frontiers in Oncology.

Implementation of clinical sequencing for molecular profiling in patients with advanced cancer.

K. Nishio, K. Naoki, K. Nakagawa, 2021, Cancer biomarkers : section A of Disease markers.

New Era for Next-Generation Sequencing in Japan

Kazuko Sakai, Kazuhiko Nakagawa, Kazuya Fukuoka, 2019, Cancers.

Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474

N. Saijo, K. Nishio, H. Fukumoto, 2004, Cancer Research.

The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma

M. Kudo, S. Hagiwara, Hobyung Chung, 2011, Journal of Gastroenterology.

Enhanced expression of nuclear factor I/B in oxaliplatin‐resistant human cancer cell lines

H. Izumi, K. Kohno, K. Nishio, 2011, Cancer science.

Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy

A. Oshima, H. K. Kim, I. Choi, 2010, The Pharmacogenomics Journal.

Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib

N. Saijo, K. Nishio, T. Kuroki, 2005, Clinical Cancer Research.

Mitogen‐activated protein kinase phosphatase‐1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor‐tyrosine kinase

K. Nishio, K. Takeuchi, Fumiaki Ito, 2009, The FEBS journal.

Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis

K. Nishio, Yukio Fujiwara, M. Ueda, 2022, PNAS nexus.

CIS‐diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung‐cancer cells

T. Ohira, N. Saijo, Y. Fujiwara, 1993, International journal of cancer.

SOX 4 is a direct target gene of FRA-2 and induces expression of HDAC 8 in adult T-cell leukemia / lymphoma

K. Nishio, O. Yoshie, T. Arao, 2013 .

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

K. Nishio, J. Tanizaki, K. Nakagawa, 2018, Cancer science.

Characterisation of a vindesine-resistant human small-cell lung cancer cell line.

N. Saijo, K. Nishio, M. Nishio, 1993, British Journal of Cancer.

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.

T. Mitsudomi, S. Tomida, K. Nishio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan

Y. Yatabe, K. Nishio, K. Togo, 2020, JTO clinical and research reports.

Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

Kaoru Tanaka, K. Nishio, T. Satoh, 2013, Cancer science.

Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer.

M. Kudo, K. Nishio, Y. Takeyama, 2012, Japanese journal of clinical oncology.

Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, H. Matsuoka, 2011, Anticancer research.

Detailed structural analysis on both human MRP5 and mouse mrp5 transcripts.

N. Saijo, K. Nishio, H. Kuh, 2000, Gene.

Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

M. Kudo, Y. Minami, K. Ueshima, 2022, Journal of Clinical Oncology.

Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis.

K. Nishio, K. Sakai, T. Kawamura, 2020, Journal of dermatological science.

Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial

Kaoru Tanaka, K. Nishio, K. Sakai, 2021, Medical Oncology.

MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations

K. Okuno, S. Tomida, M. D. De Velasco, 2014, Molecular Cancer Therapeutics.

Cancer Biology and Signal Transduction MEK Inhibitor for Gastric Cancer with MEK 1 Gene Mutations

K. Okuno, S. Tomida, K. Nishio, 2014 .

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

Tohru Utsunomiya, Masatoshi Kudo, Mitsuo Shimada, 2013, Hepatology.

MET amplification as a potential therapeutic target in gastric cancer

K. Nishio, I. Okamoto, H. Taniguchi, 2012, Oncotarget.

AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor

N. Saijo, H. Yokote, K. Nishio, 2007, Clinical Cancer Research.

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer

Y. Ohe, K. Nishio, Kazuhisa Takahashi, 2014, PloS one.

Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma

N. Matsumura, K. Nishio, K. Sakai, 2021, bioRxiv.

Present state and prospects of measurement technologies for analysis of circulating tumor cell

Hyonchol Kim, Y. Miyagi, K. Nishio, 2011 .

A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood

K. Nishio, K. Nakagawa, S. Shimizu, 2020, Case Reports in Oncology.

Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers.

N. Saijo, K. Nishio, H. Fukumoto, 2002, Experimental biology and medicine.

The MRP family and anticancer drug metabolism.

K. Nishio, S. Tanabe, T. Suzuki, 2001, Current drug metabolism.

Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis

H. Ogata, M. Kudo, T. Sakurai, 2021, Molecular oncology.

Lymph node metastatic melanoma from ungual melanoma: Identification of somatic mutations in KIT and LZTR1

A. Kawada, K. Nishio, N. Oiso, 2018, The Journal of dermatology.

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

K. Nishio, T. Satoh, T. Tsunoda, 2012, Cancer science.

Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells

Kazuya Fukuoka, N. Saijo, H. Yokote, 1999, Japanese journal of cancer research : Gann.

Characterization of an etoposide-resistant human small-cell lung cancer cell line

N. Saijo, Y. Fujiwara, K. Nishio, 2008, Cancer Chemotherapy and Pharmacology.

The H3K27 demethylase, Utx, regulates adipogenesis in a differentiation stage-dependent manner

S. Tomida, K. Nishio, H. Okada, 2017, PloS one.

EphA 4 promotes cell proliferation and migration through a novel EphA 4-FGFR 1 signaling pathway in the human glioma U 251 cell line

T. Itakura, H. Yokote, K. Nishio, 2008 .

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma

K. Nishio, Ken Kato, T. Hamaguchi, 2014, Oncotarget.

Curcumin β-D-Glucuronide Modulates an Autoimmune Model of Multiple Sclerosis with Altered Gut Microbiota in the Ileum and Feces

K. Nishio, Ikuo Tsunoda, H. Kakeya, 2021, Frontiers in Cellular and Infection Microbiology.

Decreased expression of T‐cell‐associated immune markers predicts poor prognosis in patients with follicular lymphoma

K. Nishio, I. Matsumura, K. Sakai, 2021, Cancer science.

Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report

M. Kudo, S. Hagiwara, Y. Komeda, 2020, World journal of clinical cases.

Emerging ethnic differences in lung cancer therapy

N. Saijo, K. Nishio, N. Yamamoto, 2008, British Journal of Cancer.

Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer

K. Okuno, M. D. De Velasco, K. Nishio, 2013, Molecular and clinical oncology.

Heregulin as a novel cetuximab-resistace factor in colorectal cancer.

P. Jänne, N. Saijo, M. Fukuoka, 2010 .

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study)

K. Nishio, H. Matsuoka, Y. Otake, 2017, BMC Cancer.

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk

M. Fukuoka, K. Nishio, T. Satoh, 2007, International journal of cancer.

Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma

M. Kudo, Y. Minami, S. Hagiwara, 2016, Digestive Diseases.

Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells

W. Nishio, C. Ohbayashi, M. D. De Velasco, 2013, Cancer medicine.

Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells.

K. Sugioka, K. Nishio, Y. Shimomura, 2012, Investigative ophthalmology & visual science.

What can and cannot be done using a microarray analysis? Treatment stratification and clinical applications in oncology.

K. Nishio, T. Arao, Kazuko Matsumoto, 2011, Biological & pharmaceutical bulletin.

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma

Y. Nishimura, Kaoru Tanaka, K. Nishio, 2013, Cancer medicine.

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

K. Nishio, I. Okamoto, H. Yamaguchi, 2011, British Journal of Cancer.

Integrated analysis of whole genome exon array and array‐comparative genomic hybridization in gastric and colorectal cancer cells

K. Nishio, K. Yanagihara, M. Sekijima, 2012, Cancer science.

Expression of BAF57 in ovarian cancer cells and drug sensitivity

H. Izumi, K. Nishio, T. Hachisuga, 2015, Cancer science.

EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy

Hiroshi Nishio, Hiroshi Tsuda, Daisuke Aoki, 2012, Genes, chromosomes & cancer.

EGFR mutation up-regulates EGR1 expression through the ERK pathway.

Kaoru Tanaka, H. Yokote, K. Nishio, 2009, Anticancer research.

Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk

K. Haruma, J. Hata, K. Nishio, 2016, Journal of gastroenterology and hepatology.

Uterine angioleiomyoma with disseminated intravascular coagulation: a case report

N. Matsumura, K. Nishio, K. Sakai, 2023, BMC Women's Health.

RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).

K. Nishio, S. Ikeda, A. Zimmermann, 2020 .

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

T. Mitsudomi, S. Akinaga, K. Kubota, 2016, ESMO Open.

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer

M. D. De Velasco, K. Nishio, Y. Hatanaka, 2015, Journal of Translational Medicine.

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib

Kaoru Tanaka, K. Nishio, J. Tanizaki, 2021, International Journal of Clinical Oncology.

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

K. Nishio, K. Azuma, T. Hoshino, 2020, Scientific Reports.

Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells

N. Saijo, K. Nishio, Jin-Hyoung Kang, 2004, Anti-cancer drugs.

Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1

M. Kudo, Y. Minami, S. Hagiwara, 2020, Liver Cancer.

A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).

Y. Ichinose, H. Saka, K. Kiura, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.

K. Nishio, K. Nakagawa, M. Takeda, 2019, Clinical breast cancer.

Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)

Kaoru Tanaka, K. Nishio, H. Matsuoka, 2022, The oncologist.

Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.

K. Nishio, H. Matsuoka, K. Sakai, 2017, Biomedical reports.

Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine

K. Nishio, H. Matsuoka, K. Sakai, 2017, International Journal of Behavioral Medicine.

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

R. Kaiser, K. Nishio, T. Satoh, 2010, Molecular Cancer Therapeutics.

Dimerization and the signal transduction pathway of a smallin‐frame deletion in the epidermal growth factor receptor

N. Saijo, K. Nishio, T. Tamura, 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

I. Hyodo, K. Nishio, K. Muro, 2018 .

Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.

Kaoru Tanaka, K. Nishio, Y. Hasegawa, 2021, European journal of cancer.

Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11

T. Ohira, N. Saijo, K. Nishio, 1995, Japanese journal of cancer research : Gann.

Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.

K. Nishio, K. Kunimasa, F. Imamura, 2019, Lung cancer.

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed

K. Nishio, K. Nakagawa, M. Takeda, 2019, OncoTargets and therapy.

JNK-Mediated FOXO Expression Plays a Critical Role in EGFR Tyrosine Kinase Inhibitor-Induced BIM Expression and Apoptosis

K. Nishio, K. Takeuchi, Fumiaki Ito, 2012 .

Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.

J. Soh, T. Mitsudomi, K. Nishio, 2020, Clinical lung cancer.

Epidermal growth factor receptor lacking C‐terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor

Kaoru Tanaka, H. Yokote, K. Nishio, 2009, Cancer science.

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.

Kazuko Sakai, Taroh Satoh, Kazuhiko Nakagawa, 2011, Biochemical and biophysical research communications.

Phorbol ester and okadaic acid-resistant cells: the crossroads of signal transduction and drug resistance.

N. Saijo, K. Nishio, H. Arioka, 1995, The American journal of medicine.

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

K. Nishio, T. Satoh, I. Okamoto, 2015, Oncotarget.

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening

T. Ohira, N. Ikeda, T. Mitsudomi, 2023, Cancers.

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

K. Nishio, C. Sato, K. Nakagawa, 2021, Thoracic cancer.

Slug Increases Sensitivity To Tubulin Binding Agents Via The Downregulation Of Beta III And IVa-Tubulin In Lung Cancer Cells

W. Nishio, N. Saijo, K. Nishio, 2012, ATS 2012.

Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

M. Kudo, N. Saijo, Kaoru Tanaka, 2010, Clinical Cancer Research.

Integrin-linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma.

T. Mitsudomi, K. Nishio, T. Chikugo, 2021, Oncology letters.

Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.

Y. Ishikawa, K. Nishio, M. Nishio, 2007, Chest.

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

Shinichiro Suzuki, Shigeki Shimizu, Kazuko Sakai, 2019, Scientific Reports.

Next-generation sequencing–based clinical testing for lung cancer in Japan

K. Nishio, K. Nakagawa, M. Takeda, 2017 .

Multiplexed Diagnostics for Precision Medicine in Lung Cancer

K. Nishio, 2016 .

Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray.

J. Usuda, H. Kato, T. Ohira, 2002, Oncology reports.

Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

Kazuko Sakai, Tatsuo Ohira, Kazuhiko Nakagawa, 2016, Oncotarget.

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression

T. Mitsudomi, K. Nishio, S. Shimizu, 2016, PloS one.

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis

K. Nishio, T. Itoh, Takayuki Takahashi, 2019, Journal of clinical and experimental hematopathology : JCEH.

Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells

K. Nishio, T. Takata, Y. Fujita, 2016, Archives of pharmacal research.

Real‐world study of next‐generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan

K. Nishio, M. Nishio, Toshiaki Takahashi, 2023, Cancer science.

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors

T. Mitsudomi, H. Handa, Kaoru Tanaka, 2020, The oncologist.

Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.

N. Saijo, K. Kiura, M. Tanimoto, 2006, Lung cancer.

2169 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma

K. Okuno, S. Tomida, K. Nishio, 2015 .

Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel

H. Feilotter, B. Tops, R. Franco, 2014 .

Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism.

K. Nishio, A. Shiotani, Y. Fujita, 2015, Current pharmaceutical design.

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

K. Nishio, K. Nakagawa, K. Sakai, 2023, JTO clinical and research reports.

Detection of Proteins that Recognize Platinum‐modified DNA Using Gel Mobility Shift Assay

N. Saijo, Y. Fujiwara, K. Nishio, 1990, Japanese journal of cancer research : Gann.

Translational and clinical studies of target-based cancer therapy

N. Saijo, K. Nishio, T. Tamura, 2003, International Journal of Clinical Oncology.

Problems in the development of target-based drugs

N. Saijo, K. Nishio, T. Tamura, 2000, Cancer Chemotherapy and Pharmacology.

A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial

K. Nishio, K. Muro, Yoshiyuki Yamamoto, 2023, Targeted Oncology.

Gene Expression Profiling of Exposure to TZT-1027, a Novel Microtubule-Interfering Agent, in Non-Small Cell Lung Cancer PC-14 Cells and Astrocytes

N. Saijo, K. Nishio, T. Natsume, 2004, Investigational New Drugs.

Strategy for the development of novel anticancer drugs

N. Saijo, K. Nishio, T. Tamura, 2003, Cancer Chemotherapy and Pharmacology.

Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.

K. Nishio, Y. Kameda, F. Oshita, 2000, Oncology reports.

Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro

M. Tanimoto, K. Nishio, T. Natsume, 2006, The Pharmacogenomics Journal.

In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.

Kazuko Sakai, N. Saijo, H. Yokote, 2006, The Biochemical journal.

Signal Transduction and Drug Sensitivity

K. Nishio, 2006 .

Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk

K. Nishio, T. Kato, 2006, Respirology.

Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines.

N. Saijo, Y. Fujiwara, K. Nishio, 1993, Cancer research.

MRP5b/SMRP mRNA is Highly Expressed in Metallothionein-Deficient Mouse Liver

A. Naganuma, K. Nishio, Toshihiro Suzuki, 2003 .

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing

K. Goto, K. Nishio, Y. Nakanishi, 2018, Cancer science.

cDNA cloning of a short type of multidrug resistance protein homologue, SMRP, from a human lung cancer cell line.

N. Saijo, K. Nishio, H. Kurokawa, 1997, Biochemical and biophysical research communications.

Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells

K. Nishio, T. Takeda, S. Nishida, 2023, Cell proliferation.

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.

K. Nishio, K. Azuma, N. Yamamoto, 2023, Clinical lung cancer.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, S. Hattori, T. Kinoshita, 2022 .

In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance

N. Saijo, K. Nishio, H. Arioka, 2005, Journal of Cancer Research and Clinical Oncology.

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing

K. Nishio, K. Sakai, K. Ino, 2019, Scientific Reports.

Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)

Shingo Matsumoto, Daisuke Kotani, Chikashi Ishioka, 2018, Cancer science.

Establishment of a CPT-11-resistant human ovarian cancer cell line.

K. Nishio, T. Kijima, N. Kubota, 1994, Anticancer research.

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

K. Nishio, M. Inoue, K. Kunimasa, 2018, Annals of Oncology.

Biomarker Research for Development of Molecular Target Agents

K. Nishio, T. Arao, 2009 .

Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model

M. D. De Velasco, K. Nishio, Y. Kura, 2021, Cancers.

Abstract 4699: Preclinical activity of the AKT inhibitor AZD5363 in PTEN-deficient mouse models of prostate cancer

K. Nishio, B. Davies, M. Velasco, 2015 .

Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements

K. Okuno, S. Tomida, K. Nishio, 2014 .

Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline.

K. Nishio, Y. Heike, E. Podack, 1994, Gene therapy.

P2-290: Phase II study of S-1 in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based regimen

Y. Ohe, K. Nishio, T. Tamura, 2007 .

Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies

K. Kiura, K. Nishio, K. Kunimasa, 2023, International journal of cancer.

Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy

Yosuke Tanaka, Y. Tachimori, Teruhiko Yoshida, 2015, PloS one.

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519

N. Saijo, K. Nishio, Takashi Nakamura, 2001, Japanese journal of cancer research : Gann.

Ouabain‐resistant non‐small‐cell lung‐cancer CELL LINE SHOWS COLLATERAL SENSITIVITY TO cis‐diamminedichloroplatinum(II) (CDDP)

N. Saijo, K. Nishio, M. Adachi, 1994, International journal of cancer.

Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells.

J. Usuda, N. Saijo, K. Nishio, 1999, International journal of oncology.

RASGRP 2 Suppresses Apoptosis via Inhibition of ROS Production in Vascular Endothelial Cells

K. Nagamine, K. Nishio, T. Hori, 2018 .

Phylloid hypomelanosis associated with a mosaic trisomy 13 in the 13q31.3‐qter region: atypical phylloid distribution and typical hypomelanosis

A. Kawada, K. Nishio, N. Oiso, 2017, Pigment cell & melanoma research.

Abstract 1568: A2aR inhibition enhances the antitumor activity of CTLA4 blockade in mouse Pten-deficient prostate cancer

K. Nishio, M. Velasco, Y. Kura, 2021, Immunology.

Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.

M. Kudo, Tomohiro Watanabe, M. Takenaka, 2023, International journal of clinical oncology.

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Kaoru Tanaka, K. Nishio, I. Okamoto, 2012, Clinical Cancer Research.

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

K. Nishio, K. Azuma, T. Hoshino, 2020, Scientific Reports.

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile

Masanori Kato, Kimihiro Ito, K. Nishio, 2013, Molecular Cancer Therapeutics.

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Y. Ichinose, K. Kiura, K. Goto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, K. Azuma, S. Hattori, 2016, Scientific Reports.

Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.

T. Ohira, N. Ikeda, T. Nagao, 2014, Lung cancer.

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Lung cancer.

EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line

T. Itakura, H. Yokote, K. Nishio, 2008, Molecular Cancer Therapeutics.

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production

M. D. De Velasco, K. Nishio, H. Shiozaki, 2013, Oncotarget.

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

P. Jänne, M. Fukuoka, K. Nishio, 2009, Clinical Cancer Research.

1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors

R. Kaiser, K. Nishio, T. Satoh, 2009 .

Enhanced expression of nuclear factor I/B in oxaliplatin‐resistant human cancer cell lines

H. Izumi, K. Kohno, K. Nishio, 2011, Cancer science.

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

K. Nishio, K. Nakagawa, H. Hayashi, 2014, Drug design, development and therapy.

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

M. Kudo, N. Saijo, K. Nishio, 2011, Molecular Cancer Therapeutics.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, K. Azuma, S. Hattori, 2016, Scientific Reports.

Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell‐cycle‐associated genes

Y. Sasaguri, H. Izumi, K. Kohno, 2010, Cancer science.

Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab

P. Jänne, K. Zejnullahu, M. Fukuoka, 2012 .

721 Novel Single Nucleotide Polymorphism Markers for Low Dose Aspirin-Associated Small Bowel Bleeding: A DMET Microarray Profiling Study

K. Haruma, K. Nishio, Y. Fujimura, 2014 .

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.

T. Mitsudomi, S. Tomida, K. Nishio, 2015, Lung cancer.

Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III

T. Itakura, K. Nishio, J. Fukai, 2008, Cancer science.

Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS.

K. Yonemori, C. Shimizu, Y. Fujiwara, 2009, Journal of proteome research.